ESPR Aims to Diversify With Rare Liver Disease Candidate, Stock Up
Yahoo Finance · Oct 17, 2025 · Chemomab Therapeutics Ltd DRC (CMMB)
Esperion selects ESP-2001 as a preclinical candidate for primary sclerosing cholangitis, a rare liver disease, aiming to begin clinical studies in 2026.
Not investment advice. Cached headline, not a full reprint.